Share Email Print
cover

Proceedings Paper

Enhancement mechanism of FCLA-1O2 chemiluminescence by human serum albumin
Author(s): Jing Zhou; Da Xing; Qun Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Fluoresceinyl Cypridina Lucifenn Analog (FCLA) is a reactive oxygen species (ROS) specific chemiluminescence (CL) probe. Its detection efficiency of singlet oxygen (102)couldbe significantly enhanced in the presence of human serum albumin (HSA). The enhancement mechanism of HSA-FCLA CL is studied in the current work by means ofdirect CL measurement and spectroscopy. The results show that, FCLA can combine with HSA. HSA is an effective 1O2 quencher. It can react with 102 and produce a protein carbonyl group with an elevated energy state. The HSA protein carbonyl group can transfer its energy to FCLA in the FCLA-HSA complex. Via this irradiative de-excitation pathway of the excited FCLA, luminescence production from FCLA is greatly enhanced, in addition to the chemiluminescence from the direct interaction of FCLA and 102 FCLA has been reported for cancer diagnosis in vivo. Considering HSA is a natural protein that is present in all parts of a human body, the efficacy of FCLA used in vivo is expected to be enhanced through the coupling of FCLA and HSA.

Paper Details

Date Published: 27 October 2006
PDF: 6 pages
Proc. SPIE 6047, Fourth International Conference on Photonics and Imaging in Biology and Medicine, 60473G (27 October 2006); doi: 10.1117/12.710725
Show Author Affiliations
Jing Zhou, South China Normal Univ. (China)
Da Xing, South China Normal Univ. (China)
Qun Chen, South China Normal Univ. (China)
HealthONE Alliance (United States)


Published in SPIE Proceedings Vol. 6047:
Fourth International Conference on Photonics and Imaging in Biology and Medicine
Kexin Xu; Qingming Luo; Da Xing; Alexander V. Priezzhev; Valery V. Tuchin, Editor(s)

© SPIE. Terms of Use
Back to Top